Monitor for Phase 1 trial initiation and enrollment updates, which will provide the first clinical data on SZN-8141. The DME market is competitive with existing anti-VEGF therapies, so differentiation data will be critical.
Price Chart
Executive Summary
Surrozen received FDA clearance to begin clinical trials of SZN-8141 for diabetic macular edema, a key pipeline milestone for this early-stage biotech. The IND clearance allows the company to initiate first-in-human studies, but no clinical data or commercial timeline has been disclosed.
Key Facts
- FDA cleared Surrozen's IND application for SZN-8141
- SZN-8141 is being developed for diabetic macular edema (DME)
- This is a preclinical-to-clinical transition milestone for Surrozen
Financial Impact
No financial terms disclosed; IND clearance is a regulatory milestone with no direct revenue impact yet
Risk Factors
- SZN-8141 is early-stage with no clinical data yet; IND clearance does not guarantee successful trial outcomes
- DME market is crowded with established therapies (e.g., Eylea, Vabysmo), creating high bar for differentiation
- Surrozen is a small-cap biotech with limited financial resources; cash runway and potential dilution are key risks
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373778 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | SC 13D/A | $25.48 | awaiting T+5 | — | $29.53 (+15.89%) |
Oct 20, 2026 7d ago | 8-K | $25.32 | awaiting T+5 | — | $29.53 (+16.63%) |
Oct 20, 2026 7d ago | Press Release | $25.32 | awaiting T+5 | — | $29.53 (+16.63%) |
Oct 7, 2026 20d ago | SC 13G/A | $27.97 $25.07 | ▼ −10.37% | ▼ −10.09% | $29.53 (+5.58%) |
Oct 2, 2026 25d ago | 8-K | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $29.53 (+0.72%) |
Oct 2, 2026 25d ago | Press Release | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $29.53 (+0.72%) |
Oct 1, 2026 26d ago | SC 13G | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $29.53 (+0.72%) |
Aug 7, 2026 11w ago | 25-NSE | $25.09 $23.78 | ▼ −5.22% | ▼ −5.17% | $29.53 (+17.70%) |
May 4, 2026 25w ago | Insider Cluster | $32.07 $29.28 | ▼ −8.70% | ▼ −11.64% | $29.53 (−7.92%) |
Mar 23, 2026 31w ago | S-3 | $25.00 $29.13 | ▼ −16.52% | ▼ −16.94% | $29.53 (−18.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers